Pediatric Germ Cell Tumors: Protocol Update for Pathologists
ABSTRACT The therapy for pediatric germ cell tumors has historically been widely variable and institution dependent. The efforts to provide consistent, biology-driven therapy through Intergroup protocols has been a relatively recent phenomenon that has provided the framework for future protocol desi...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
1998 |
|---|
| Umfang: |
8 |
|---|
| Reproduktion: |
Springer Online Journal Archives 1860-2002 |
|---|---|
| Übergeordnetes Werk: |
in: Pediatric and developmental pathology - 1998, 1(1998) vom: Apr., Seite 328-335 |
| Übergeordnetes Werk: |
volume:1 ; year:1998 ; month:04 ; pages:328-335 ; extent:8 |
| Links: |
|---|
| Katalog-ID: |
NLEJ207478554 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLEJ207478554 | ||
| 003 | DE-627 | ||
| 005 | 20210706231052.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 070528s1998 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)NLEJ207478554 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 245 | 1 | 0 | |a Pediatric Germ Cell Tumors: Protocol Update for Pathologists |
| 264 | 1 | |c 1998 | |
| 300 | |a 8 | ||
| 336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
| 337 | |a nicht spezifiziert |b z |2 rdamedia | ||
| 338 | |a nicht spezifiziert |b zu |2 rdacarrier | ||
| 520 | |a ABSTRACT The therapy for pediatric germ cell tumors has historically been widely variable and institution dependent. The efforts to provide consistent, biology-driven therapy through Intergroup protocols has been a relatively recent phenomenon that has provided the framework for future protocol designs. The first Intergroup protocols confirmed that stage I malignant testicular germ cell tumors and immature teratomas at all sites in children could be treated with surgery alone followed by close observation. Future protocols currently in the planning stages may extend this low-risk category to stage I ovarian germ cell tumors of all histologic types. Low-stage extragonadal germ cell tumors may be placed in a new intermediate risk category. Particular pathologic issues that were raised and reported during the first protocols and that may impact on future protocol design include the presence and size of foci of endodermal sinus tumors within low-stage immature teratomas at all sites. Accurate staging will grow more critical in future protocols. The ability to recruit international cooperative groups will determine the success of chemotherapy tailored to specific subgroups that now must be lumped for statistical purposes. Lastly, companion biologic studies will be critical to defining the different subtypes of germ cell tumors and to determining predictors of biologic behavior. | ||
| 533 | |f Springer Online Journal Archives 1860-2002 | ||
| 700 | 1 | |a Perlman, Elizabeth J. |4 oth | |
| 700 | 1 | |a Hawkins, Edith P. |4 oth | |
| 773 | 0 | 8 | |i in |t Pediatric and developmental pathology |d 1998 |g 1(1998) vom: Apr., Seite 328-335 |w (DE-627)NLEJ188985328 |w (DE-600)1480654-x |x 1615-5742 |7 nnns |
| 773 | 1 | 8 | |g volume:1 |g year:1998 |g month:04 |g pages:328-335 |g extent:8 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s100249900048 |
| 912 | |a GBV_USEFLAG_U | ||
| 912 | |a ZDB-1-SOJ | ||
| 912 | |a GBV_NL_ARTICLE | ||
| 951 | |a AR | ||
| 952 | |d 1 |j 1998 |c 4 |h 328-335 |g 8 | ||
| matchkey_str |
article:16155742:1998----::eitigrcltmrpoooudtf |
|---|---|
| hierarchy_sort_str |
1998 |
| publishDate |
1998 |
| allfields |
(DE-627)NLEJ207478554 DE-627 ger DE-627 rakwb eng Pediatric Germ Cell Tumors: Protocol Update for Pathologists 1998 8 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier ABSTRACT The therapy for pediatric germ cell tumors has historically been widely variable and institution dependent. The efforts to provide consistent, biology-driven therapy through Intergroup protocols has been a relatively recent phenomenon that has provided the framework for future protocol designs. The first Intergroup protocols confirmed that stage I malignant testicular germ cell tumors and immature teratomas at all sites in children could be treated with surgery alone followed by close observation. Future protocols currently in the planning stages may extend this low-risk category to stage I ovarian germ cell tumors of all histologic types. Low-stage extragonadal germ cell tumors may be placed in a new intermediate risk category. Particular pathologic issues that were raised and reported during the first protocols and that may impact on future protocol design include the presence and size of foci of endodermal sinus tumors within low-stage immature teratomas at all sites. Accurate staging will grow more critical in future protocols. The ability to recruit international cooperative groups will determine the success of chemotherapy tailored to specific subgroups that now must be lumped for statistical purposes. Lastly, companion biologic studies will be critical to defining the different subtypes of germ cell tumors and to determining predictors of biologic behavior. Springer Online Journal Archives 1860-2002 Perlman, Elizabeth J. oth Hawkins, Edith P. oth in Pediatric and developmental pathology 1998 1(1998) vom: Apr., Seite 328-335 (DE-627)NLEJ188985328 (DE-600)1480654-x 1615-5742 nnns volume:1 year:1998 month:04 pages:328-335 extent:8 http://dx.doi.org/10.1007/s100249900048 GBV_USEFLAG_U ZDB-1-SOJ GBV_NL_ARTICLE AR 1 1998 4 328-335 8 |
| spelling |
(DE-627)NLEJ207478554 DE-627 ger DE-627 rakwb eng Pediatric Germ Cell Tumors: Protocol Update for Pathologists 1998 8 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier ABSTRACT The therapy for pediatric germ cell tumors has historically been widely variable and institution dependent. The efforts to provide consistent, biology-driven therapy through Intergroup protocols has been a relatively recent phenomenon that has provided the framework for future protocol designs. The first Intergroup protocols confirmed that stage I malignant testicular germ cell tumors and immature teratomas at all sites in children could be treated with surgery alone followed by close observation. Future protocols currently in the planning stages may extend this low-risk category to stage I ovarian germ cell tumors of all histologic types. Low-stage extragonadal germ cell tumors may be placed in a new intermediate risk category. Particular pathologic issues that were raised and reported during the first protocols and that may impact on future protocol design include the presence and size of foci of endodermal sinus tumors within low-stage immature teratomas at all sites. Accurate staging will grow more critical in future protocols. The ability to recruit international cooperative groups will determine the success of chemotherapy tailored to specific subgroups that now must be lumped for statistical purposes. Lastly, companion biologic studies will be critical to defining the different subtypes of germ cell tumors and to determining predictors of biologic behavior. Springer Online Journal Archives 1860-2002 Perlman, Elizabeth J. oth Hawkins, Edith P. oth in Pediatric and developmental pathology 1998 1(1998) vom: Apr., Seite 328-335 (DE-627)NLEJ188985328 (DE-600)1480654-x 1615-5742 nnns volume:1 year:1998 month:04 pages:328-335 extent:8 http://dx.doi.org/10.1007/s100249900048 GBV_USEFLAG_U ZDB-1-SOJ GBV_NL_ARTICLE AR 1 1998 4 328-335 8 |
| allfields_unstemmed |
(DE-627)NLEJ207478554 DE-627 ger DE-627 rakwb eng Pediatric Germ Cell Tumors: Protocol Update for Pathologists 1998 8 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier ABSTRACT The therapy for pediatric germ cell tumors has historically been widely variable and institution dependent. The efforts to provide consistent, biology-driven therapy through Intergroup protocols has been a relatively recent phenomenon that has provided the framework for future protocol designs. The first Intergroup protocols confirmed that stage I malignant testicular germ cell tumors and immature teratomas at all sites in children could be treated with surgery alone followed by close observation. Future protocols currently in the planning stages may extend this low-risk category to stage I ovarian germ cell tumors of all histologic types. Low-stage extragonadal germ cell tumors may be placed in a new intermediate risk category. Particular pathologic issues that were raised and reported during the first protocols and that may impact on future protocol design include the presence and size of foci of endodermal sinus tumors within low-stage immature teratomas at all sites. Accurate staging will grow more critical in future protocols. The ability to recruit international cooperative groups will determine the success of chemotherapy tailored to specific subgroups that now must be lumped for statistical purposes. Lastly, companion biologic studies will be critical to defining the different subtypes of germ cell tumors and to determining predictors of biologic behavior. Springer Online Journal Archives 1860-2002 Perlman, Elizabeth J. oth Hawkins, Edith P. oth in Pediatric and developmental pathology 1998 1(1998) vom: Apr., Seite 328-335 (DE-627)NLEJ188985328 (DE-600)1480654-x 1615-5742 nnns volume:1 year:1998 month:04 pages:328-335 extent:8 http://dx.doi.org/10.1007/s100249900048 GBV_USEFLAG_U ZDB-1-SOJ GBV_NL_ARTICLE AR 1 1998 4 328-335 8 |
| allfieldsGer |
(DE-627)NLEJ207478554 DE-627 ger DE-627 rakwb eng Pediatric Germ Cell Tumors: Protocol Update for Pathologists 1998 8 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier ABSTRACT The therapy for pediatric germ cell tumors has historically been widely variable and institution dependent. The efforts to provide consistent, biology-driven therapy through Intergroup protocols has been a relatively recent phenomenon that has provided the framework for future protocol designs. The first Intergroup protocols confirmed that stage I malignant testicular germ cell tumors and immature teratomas at all sites in children could be treated with surgery alone followed by close observation. Future protocols currently in the planning stages may extend this low-risk category to stage I ovarian germ cell tumors of all histologic types. Low-stage extragonadal germ cell tumors may be placed in a new intermediate risk category. Particular pathologic issues that were raised and reported during the first protocols and that may impact on future protocol design include the presence and size of foci of endodermal sinus tumors within low-stage immature teratomas at all sites. Accurate staging will grow more critical in future protocols. The ability to recruit international cooperative groups will determine the success of chemotherapy tailored to specific subgroups that now must be lumped for statistical purposes. Lastly, companion biologic studies will be critical to defining the different subtypes of germ cell tumors and to determining predictors of biologic behavior. Springer Online Journal Archives 1860-2002 Perlman, Elizabeth J. oth Hawkins, Edith P. oth in Pediatric and developmental pathology 1998 1(1998) vom: Apr., Seite 328-335 (DE-627)NLEJ188985328 (DE-600)1480654-x 1615-5742 nnns volume:1 year:1998 month:04 pages:328-335 extent:8 http://dx.doi.org/10.1007/s100249900048 GBV_USEFLAG_U ZDB-1-SOJ GBV_NL_ARTICLE AR 1 1998 4 328-335 8 |
| allfieldsSound |
(DE-627)NLEJ207478554 DE-627 ger DE-627 rakwb eng Pediatric Germ Cell Tumors: Protocol Update for Pathologists 1998 8 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier ABSTRACT The therapy for pediatric germ cell tumors has historically been widely variable and institution dependent. The efforts to provide consistent, biology-driven therapy through Intergroup protocols has been a relatively recent phenomenon that has provided the framework for future protocol designs. The first Intergroup protocols confirmed that stage I malignant testicular germ cell tumors and immature teratomas at all sites in children could be treated with surgery alone followed by close observation. Future protocols currently in the planning stages may extend this low-risk category to stage I ovarian germ cell tumors of all histologic types. Low-stage extragonadal germ cell tumors may be placed in a new intermediate risk category. Particular pathologic issues that were raised and reported during the first protocols and that may impact on future protocol design include the presence and size of foci of endodermal sinus tumors within low-stage immature teratomas at all sites. Accurate staging will grow more critical in future protocols. The ability to recruit international cooperative groups will determine the success of chemotherapy tailored to specific subgroups that now must be lumped for statistical purposes. Lastly, companion biologic studies will be critical to defining the different subtypes of germ cell tumors and to determining predictors of biologic behavior. Springer Online Journal Archives 1860-2002 Perlman, Elizabeth J. oth Hawkins, Edith P. oth in Pediatric and developmental pathology 1998 1(1998) vom: Apr., Seite 328-335 (DE-627)NLEJ188985328 (DE-600)1480654-x 1615-5742 nnns volume:1 year:1998 month:04 pages:328-335 extent:8 http://dx.doi.org/10.1007/s100249900048 GBV_USEFLAG_U ZDB-1-SOJ GBV_NL_ARTICLE AR 1 1998 4 328-335 8 |
| language |
English |
| source |
in Pediatric and developmental pathology 1(1998) vom: Apr., Seite 328-335 volume:1 year:1998 month:04 pages:328-335 extent:8 |
| sourceStr |
in Pediatric and developmental pathology 1(1998) vom: Apr., Seite 328-335 volume:1 year:1998 month:04 pages:328-335 extent:8 |
| format_phy_str_mv |
Article |
| institution |
findex.gbv.de |
| isfreeaccess_bool |
false |
| container_title |
Pediatric and developmental pathology |
| authorswithroles_txt_mv |
Perlman, Elizabeth J. @@oth@@ Hawkins, Edith P. @@oth@@ |
| publishDateDaySort_date |
1998-04-01T00:00:00Z |
| hierarchy_top_id |
NLEJ188985328 |
| id |
NLEJ207478554 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">NLEJ207478554</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20210706231052.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">070528s1998 xx |||||o 00| ||eng c</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)NLEJ207478554</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Pediatric Germ Cell Tumors: Protocol Update for Pathologists</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">1998</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">8</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">ABSTRACT The therapy for pediatric germ cell tumors has historically been widely variable and institution dependent. The efforts to provide consistent, biology-driven therapy through Intergroup protocols has been a relatively recent phenomenon that has provided the framework for future protocol designs. The first Intergroup protocols confirmed that stage I malignant testicular germ cell tumors and immature teratomas at all sites in children could be treated with surgery alone followed by close observation. Future protocols currently in the planning stages may extend this low-risk category to stage I ovarian germ cell tumors of all histologic types. Low-stage extragonadal germ cell tumors may be placed in a new intermediate risk category. Particular pathologic issues that were raised and reported during the first protocols and that may impact on future protocol design include the presence and size of foci of endodermal sinus tumors within low-stage immature teratomas at all sites. Accurate staging will grow more critical in future protocols. The ability to recruit international cooperative groups will determine the success of chemotherapy tailored to specific subgroups that now must be lumped for statistical purposes. Lastly, companion biologic studies will be critical to defining the different subtypes of germ cell tumors and to determining predictors of biologic behavior.</subfield></datafield><datafield tag="533" ind1=" " ind2=" "><subfield code="f">Springer Online Journal Archives 1860-2002</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Perlman, Elizabeth J.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Hawkins, Edith P.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">in</subfield><subfield code="t">Pediatric and developmental pathology</subfield><subfield code="d">1998</subfield><subfield code="g">1(1998) vom: Apr., Seite 328-335</subfield><subfield code="w">(DE-627)NLEJ188985328</subfield><subfield code="w">(DE-600)1480654-x</subfield><subfield code="x">1615-5742</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:1</subfield><subfield code="g">year:1998</subfield><subfield code="g">month:04</subfield><subfield code="g">pages:328-335</subfield><subfield code="g">extent:8</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://dx.doi.org/10.1007/s100249900048</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-1-SOJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_NL_ARTICLE</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">1</subfield><subfield code="j">1998</subfield><subfield code="c">4</subfield><subfield code="h">328-335</subfield><subfield code="g">8</subfield></datafield></record></collection>
|
| series2 |
Springer Online Journal Archives 1860-2002 |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)NLEJ188985328 |
| format |
electronic Article |
| delete_txt_mv |
keep |
| collection |
NL |
| remote_str |
true |
| illustrated |
Not Illustrated |
| issn |
1615-5742 |
| topic_title |
Pediatric Germ Cell Tumors: Protocol Update for Pathologists |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
zu |
| author2_variant |
e j p ej ejp e p h ep eph |
| hierarchy_parent_title |
Pediatric and developmental pathology |
| hierarchy_parent_id |
NLEJ188985328 |
| hierarchy_top_title |
Pediatric and developmental pathology |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)NLEJ188985328 (DE-600)1480654-x |
| title |
Pediatric Germ Cell Tumors: Protocol Update for Pathologists |
| spellingShingle |
Pediatric Germ Cell Tumors: Protocol Update for Pathologists |
| ctrlnum |
(DE-627)NLEJ207478554 |
| title_full |
Pediatric Germ Cell Tumors: Protocol Update for Pathologists |
| journal |
Pediatric and developmental pathology |
| journalStr |
Pediatric and developmental pathology |
| lang_code |
eng |
| isOA_bool |
false |
| recordtype |
marc |
| publishDateSort |
1998 |
| contenttype_str_mv |
zzz |
| container_start_page |
328 |
| container_volume |
1 |
| physical |
8 |
| format_se |
Elektronische Aufsätze |
| title_sort |
pediatric germ cell tumors: protocol update for pathologists |
| title_auth |
Pediatric Germ Cell Tumors: Protocol Update for Pathologists |
| abstract |
ABSTRACT The therapy for pediatric germ cell tumors has historically been widely variable and institution dependent. The efforts to provide consistent, biology-driven therapy through Intergroup protocols has been a relatively recent phenomenon that has provided the framework for future protocol designs. The first Intergroup protocols confirmed that stage I malignant testicular germ cell tumors and immature teratomas at all sites in children could be treated with surgery alone followed by close observation. Future protocols currently in the planning stages may extend this low-risk category to stage I ovarian germ cell tumors of all histologic types. Low-stage extragonadal germ cell tumors may be placed in a new intermediate risk category. Particular pathologic issues that were raised and reported during the first protocols and that may impact on future protocol design include the presence and size of foci of endodermal sinus tumors within low-stage immature teratomas at all sites. Accurate staging will grow more critical in future protocols. The ability to recruit international cooperative groups will determine the success of chemotherapy tailored to specific subgroups that now must be lumped for statistical purposes. Lastly, companion biologic studies will be critical to defining the different subtypes of germ cell tumors and to determining predictors of biologic behavior. |
| abstractGer |
ABSTRACT The therapy for pediatric germ cell tumors has historically been widely variable and institution dependent. The efforts to provide consistent, biology-driven therapy through Intergroup protocols has been a relatively recent phenomenon that has provided the framework for future protocol designs. The first Intergroup protocols confirmed that stage I malignant testicular germ cell tumors and immature teratomas at all sites in children could be treated with surgery alone followed by close observation. Future protocols currently in the planning stages may extend this low-risk category to stage I ovarian germ cell tumors of all histologic types. Low-stage extragonadal germ cell tumors may be placed in a new intermediate risk category. Particular pathologic issues that were raised and reported during the first protocols and that may impact on future protocol design include the presence and size of foci of endodermal sinus tumors within low-stage immature teratomas at all sites. Accurate staging will grow more critical in future protocols. The ability to recruit international cooperative groups will determine the success of chemotherapy tailored to specific subgroups that now must be lumped for statistical purposes. Lastly, companion biologic studies will be critical to defining the different subtypes of germ cell tumors and to determining predictors of biologic behavior. |
| abstract_unstemmed |
ABSTRACT The therapy for pediatric germ cell tumors has historically been widely variable and institution dependent. The efforts to provide consistent, biology-driven therapy through Intergroup protocols has been a relatively recent phenomenon that has provided the framework for future protocol designs. The first Intergroup protocols confirmed that stage I malignant testicular germ cell tumors and immature teratomas at all sites in children could be treated with surgery alone followed by close observation. Future protocols currently in the planning stages may extend this low-risk category to stage I ovarian germ cell tumors of all histologic types. Low-stage extragonadal germ cell tumors may be placed in a new intermediate risk category. Particular pathologic issues that were raised and reported during the first protocols and that may impact on future protocol design include the presence and size of foci of endodermal sinus tumors within low-stage immature teratomas at all sites. Accurate staging will grow more critical in future protocols. The ability to recruit international cooperative groups will determine the success of chemotherapy tailored to specific subgroups that now must be lumped for statistical purposes. Lastly, companion biologic studies will be critical to defining the different subtypes of germ cell tumors and to determining predictors of biologic behavior. |
| collection_details |
GBV_USEFLAG_U ZDB-1-SOJ GBV_NL_ARTICLE |
| title_short |
Pediatric Germ Cell Tumors: Protocol Update for Pathologists |
| url |
http://dx.doi.org/10.1007/s100249900048 |
| remote_bool |
true |
| author2 |
Perlman, Elizabeth J. Hawkins, Edith P. |
| author2Str |
Perlman, Elizabeth J. Hawkins, Edith P. |
| ppnlink |
NLEJ188985328 |
| mediatype_str_mv |
z |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| author2_role |
oth oth |
| up_date |
2024-07-06T09:48:01.166Z |
| _version_ |
1803822596013162496 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">NLEJ207478554</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20210706231052.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">070528s1998 xx |||||o 00| ||eng c</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)NLEJ207478554</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Pediatric Germ Cell Tumors: Protocol Update for Pathologists</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">1998</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">8</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">ABSTRACT The therapy for pediatric germ cell tumors has historically been widely variable and institution dependent. The efforts to provide consistent, biology-driven therapy through Intergroup protocols has been a relatively recent phenomenon that has provided the framework for future protocol designs. The first Intergroup protocols confirmed that stage I malignant testicular germ cell tumors and immature teratomas at all sites in children could be treated with surgery alone followed by close observation. Future protocols currently in the planning stages may extend this low-risk category to stage I ovarian germ cell tumors of all histologic types. Low-stage extragonadal germ cell tumors may be placed in a new intermediate risk category. Particular pathologic issues that were raised and reported during the first protocols and that may impact on future protocol design include the presence and size of foci of endodermal sinus tumors within low-stage immature teratomas at all sites. Accurate staging will grow more critical in future protocols. The ability to recruit international cooperative groups will determine the success of chemotherapy tailored to specific subgroups that now must be lumped for statistical purposes. Lastly, companion biologic studies will be critical to defining the different subtypes of germ cell tumors and to determining predictors of biologic behavior.</subfield></datafield><datafield tag="533" ind1=" " ind2=" "><subfield code="f">Springer Online Journal Archives 1860-2002</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Perlman, Elizabeth J.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Hawkins, Edith P.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">in</subfield><subfield code="t">Pediatric and developmental pathology</subfield><subfield code="d">1998</subfield><subfield code="g">1(1998) vom: Apr., Seite 328-335</subfield><subfield code="w">(DE-627)NLEJ188985328</subfield><subfield code="w">(DE-600)1480654-x</subfield><subfield code="x">1615-5742</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:1</subfield><subfield code="g">year:1998</subfield><subfield code="g">month:04</subfield><subfield code="g">pages:328-335</subfield><subfield code="g">extent:8</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://dx.doi.org/10.1007/s100249900048</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-1-SOJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_NL_ARTICLE</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">1</subfield><subfield code="j">1998</subfield><subfield code="c">4</subfield><subfield code="h">328-335</subfield><subfield code="g">8</subfield></datafield></record></collection>
|
| score |
7.4008856 |